Mar 2024 $40 M Private placement after listing $10 to $50 million 13
Nemus Bioscience, Inc.: Private sale, Mar 2024 × Investors in this round 13 investors had bought by the notice of Mar 27, 2024: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $40 M of $40 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,400,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Kaitlyn Arsenault · Executive Officer · Chief Financial Officer Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director Andrew Schwab · Director Annalisa Jenkins · Director Deborah Charych · Director Keith Ward · Director Margaret Dalesandro · Director Paul Grayson · Director Praveen Tyle · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Oppenheimer & Co. Inc. (CRD 249) · New York, New York Sold in all US states Piper Sandler & Co (CRD 665) · Minneapolis, Minnesota Sold in all US states Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 27, 2024. Read the notice at the SEC .
equity SEC Jan 2024 $50 M Private placement after listing $10 to $50 million 11
Nemus Bioscience, Inc.: Private sale, Jan 2024 × Investors in this round 11 investors had bought by the notice of Feb 12, 2024: 11 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $3,499,371
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Kaitlyn Arsenault · Executive Officer · Chief Financial Officer Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director Andrew Schwab · Director Deborah Charych · Director Keith Ward · Director Margaret Dalesandro · Director Paul Grayson · Director Praveen Tyle · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Oppenheimer & Co. Inc. (CRD 249) · New York, New York Sold in all US states Piper Sandler & Co (CRD 665) · Minneapolis, Minnesota Sold in all US states Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 12, 2024. Read the notice at the SEC .
equity, options SEC Aug 2023 $62 M Private placement after listing $50 to $250 million 12
Nemus Bioscience, Inc.: Private sale, Aug 2023 × Investors in this round 12 investors had bought by the notice of Aug 29, 2023: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $62 M of $62 M offered
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Kaitlyn Arsenault · Executive Officer · Chief Financial Officer Punit Dhillon · Executive Officer, Director · Chief Executive Officer, Chairman and Director Andrew Schwab · Director Deborah Charych · Director Keith Ward · Director Margaret Dalesandro · Director Paul Grayson · Director Praveen Tyle · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “For a description of these transactions, see the Company's Current Report on Form 8-K, as filed with the SEC on August 21, 2023.”On a merger: “"A portion of this offering is made pursuant to that certain Agreement and Plan of Merger and Reorganization, dated August 15, 2023, by and among Skye Bioscience, Inc., Aquila Merger Sub, Inc., and Bird Rock Bio, Inc. (the ""Merger Agreement"")."”Signed by Kaitlyn Arsenault, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 29, 2023. Read the notice at the SEC .
equity, debt, options SEC Nov 2018 $2 M Private placement after listing $2 to $10 million 1
Nemus Bioscience, Inc.: Private sale, Nov 2018 × Investors in this round 1 investor had bought by the notice of Nov 15, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $33 M offered; $31 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last more than a year
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Brian S. Murphy · Executive Officer, Director Douglas A. Cesario · Executive Officer Avtar L. Dhillon · Director James L. Heppell · Director Punit S. Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Includes $20MM of convertible debt and warrants to purchase 25MM shares of common stock. If warrants are exercised in full, the Issuer will receive aggregate gross proceeds of $12.5MM (included in Total Offering Amount and Total Remaining to be Sold).”Signed by Douglas A. Cesario, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 15, 2018. Read the notice at the SEC .
equity, debt, options SEC Jan 2018 $4 M Private placement after listing $2 to $10 million 2
Nemus Bioscience, Inc.: Private sale, Jan 2018 × Investors in this round 2 investors had bought by the notice of Feb 23, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $4 M of $9 M offered; $4 M still to sell
Smallest investment taken no minimum stated
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Brian S. Murphy · Executive Officer, Director Elizabeth M. Berecz · Executive Officer James L. Heppell · Director Punit S. Dhillon · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “If the warrants are exercised in full, the company will receive aggregate gross proceeds of $4,420,000. This is included in the amounts stated in Total Offering Amount and Total Remaining to be Sold.”Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 23, 2018. Read the notice at the SEC .
equity, debt, options SEC Nov 2017 $2 M Private placement after listing $2 to $10 million 2
Nemus Bioscience, Inc.: Private sale, Nov 2017 × Investors in this round 2 investors had bought by the notice of Nov 14, 2017: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Brian S. Murphy · Executive Officer, Director Cosmas N. Lykos · Executive Officer, Director Elizabeth M. Berecz · Executive Officer Douglas S. Ingram · Director Gerald W. McLaughlin · Director Thomas A. George · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “For general corporate purposes, including, without limitation, to pay down obligations and other working capital items.”Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2017. Read the notice at the SEC .
equity SEC Jan 2017 $1 M Private placement after listing Under $2 million 5
Nemus Bioscience, Inc.: Private sale, Jan 2017 × Investors in this round 5 investors had bought by the notice of Jan 13, 2017: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $2 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Brian S. Murphy · Executive Officer Cosmas N. Lykos · Executive Officer, Director Elizabeth M. Berecz · Executive Officer Douglas S. Ingram · Director Gerald W. McLaughlin · Director Thomas A. George · Director Francicso W. Mendez · Promoter · Former officer/director Yosbani W. Mendez · Promoter · Former officer/director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Roth Capital Partners, LLC (CRD 15407) · Newport Beach, California Sold in all US states Remarks in the notice On fees: “Sales Compensation - warrants to purchase 480,000 shares of common stock at an exercise price of $0.25 per share”On the use of proceeds: “Issuer intends to use proceeds of the financing to fund advancement of its proprietary cannabinoid-based therapeutics and for gen. corp. purposes (includes payment of salaries to its exec. officers and other employees in the ordinary course of business)”Signed by Elizabeth M. Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 13, 2017. Read the notice at the SEC .
equity SEC Aug 2015 $5 M Private placement after listing $2 to $10 million 15
Nemus Bioscience, Inc.: Private sale, Aug 2015 × Investors in this round 15 investors had bought by the notice of Aug 27, 2015: 15 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Nemus Bioscience, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $213,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Brian S. Murphy · Executive Officer Cosmas N. Lykos · Executive Officer, Director Douglas S. Ingram · Executive Officer, Director Elizabeth M. Berecz · Executive Officer Gerald W. McLaughlin · Director Thomas A. George · Director Francicso W. Mendez · Promoter · Former officer/director Yosbani W. Mendez · Promoter · Former officer/director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Midtown Partners & Co., LLC (CRD 104223) · New York, New York Sold in CA, FL, NJ, NY Remarks in the notice On fees: “Additional Sales Compensation-warrants to purchase 187,500 shares of common stock.”On the use of proceeds: “The Issuer will use proceeds for general working capital purposes which includes payment of salaries to its executive officers and other employees in the ordinary course of business.”Signed by Elizabeth Berecz, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 27, 2015. Read the notice at the SEC .
equity, options SEC